Promoted Content Promoted Content

X
[{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Announces Positive Top-line Results from Trial of FINTEPLA\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"$84.0 million","newsHeadline":"Advanz Pharma Announces Definitive Agreement to Acquire The Rights To A Portfolio Of Alprostadil Products","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB provides an update on Phase 2b padsevonil safety and efficacy study in epilepsy (ARISE)\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Ra Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Engage Therapeutics","pharmaFlowCategory":"D","amount":"$270\u202c.0 million","upfrontCash":"$125.0 million","newsHeadline":"UCB Acquires Engage Therapeutics for Staccato\u00ae Alprazolam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Shares Breadth of Innovative New Data from Rheumatology Portfolio for EULAR 2020 E-Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara\u00ae at Week 16 in Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA\u00ae for the Treatment of Moderate to Severe Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimekizumab Shows Positive Phase 3b Results Against Cosentyx","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB'S CIMZIA is the First and Only Biologic Approved in Europe with the Option for a Reduced Maintenance Dose for Patients Across the Full Axial Spondyloarthritis Spectrum","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Data on UCB's Vimpat\u00ae CV in Primary Generalized Tonic-Clonic Seizures Published in Journal of Neurology, Neurosurgery & Psychiatry","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Highmark","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Highmark Forges Outcomes-Based Contract with UCB for Anti-Inflammatory Drug CIMZIA\u00ae (certolizumab pegol)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Announces Positive Top-Line Results from its Third Pivotal Phase 3 Clinical Trial of FINTEPLA\u00ae in Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zogenix, Inc. Prices $200.0 Million Convertible Senior Notes Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Achieves Important Regulatory Milestone for Bimekizumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$222.7 million","upfrontCash":"Undisclosed","newsHeadline":"Zogenix, Inc. Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $30.0 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB\u2019s Anti-Epileptic Drug Vimpat[\u00ae] (lacosamide) Receives EU CHMP Positive Opinion for Primary Generalised Tonic-Clonic Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB'S Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira\u00ae in Moderate-to-Severe Psoriasis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Handl therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB Acquires Handl Therapeutics BV","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Lacerta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB Strengthens Its Gene Therapy Activities with Additional Pipeline Programs, Capabilities and Platforms","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB's VIMPAT\u00ae CV Now Approved by FDA for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric use for Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Zogenix","sponsor":"Tevard Biosciences","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"$10.0 million","newsHeadline":"Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies for Dravet Syndrome and Other Genetic Epilepsies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society's Virtual Event AES2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA Oral Solution on Dravet Syndrome Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB\u2019s Zilucoplan Shows no Relevant Effect in Immune-Mediated Necrotizing Myopathy (IMNM)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Presents New Data at Virtual AAN 2021 Showing Improved Executive Function in Lennox-Gastaut Syndrome Patients Treated with FINTEPLA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\"The New England Journal of Medicine\" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Launches Global Access Program for FINTEPLA\u00ae (Fenfluramine) Oral Solution","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Neuropore Therapies","pharmaFlowCategory":"D","amount":"$460.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from UCB's Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"M8 Pharmaceuticals and UCB Partner for Central Nervous System and Respiratory Portfolio in Mexico","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Product FINTEPLA\u00ae (Fenfluramine) Recognized for Setting a New Standard for Dravet Syndrome Treatment Outcomes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Zogenix","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Receives Orphan Drug Designation for FINTEPLA\u00ae (Fenfluramine) in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Zogenix","sponsor":"PPD","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Submits Supplemental New Drug Application for FINTEPLA\u00ae (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New BIMZELX (bimekizumab) Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at The 30th European Academy of Dermatology and Venereology (EADV) Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New FINTEPLA\u00ae (Fenfluramine) Data Show Long-Term Seizure Frequency Reductions in Patients with Lennox-Gastaut Syndrome (LGS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Showcases Key Rheumatology Data at ACR Convergence 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Top-Line Results for BIMZELX[\u00ae]\u25bc(Bimekizumab) in Phase 3 Ankylosing Spondylitis Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Submits New Drug Application for FINTEPLA\u00ae (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Top-Line Results for BIMZELX[\u00ae]\u25bc(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Receives Positive CHMP Opinion Recommending Approval of BRIVIACT[\u00ae] (brivaracetam) and VIMPAT[\u00ae] (lacosamide) in the EU for Partial-Onset Seizures in Pediatric Patients From Two to Four Years","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIMZELX[\u00ae] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Top-Line Results for BIMZELX[\u00ae]\u25bc(bimekizumab) in Phase 3 Non-Radiographic Axial Spondyloarthritis Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Zogenix","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"$1,900.0 million","newsHeadline":"UCB Completes Acquisition of Zogenix, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix To Present New Long-term Data on FINTEPLA\u00c2\u00ae (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves FINTEPLA\u00ae (fenfluramine) Oral Solution for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New UCB Data Analysis Adds to Demonstrated Efficacy of Romosozumab to Reduce the Risk of Fractures","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[\u00ae]\u25bc(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on U.S. FDA Review of Biologics License Application (BLA) for Bimekizumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Three-Year BIMZELX\u00ae (bimekizumab) Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASBMR 2022: 3D Modelling of Hip DXA Scans in Postmenopausal Women With Osteoporosis Reveals Superior Improvements in Bone Density of Romosozumab Versus Controls","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Presents Latest Data From Generalized Myasthenia Gravis Portfolio At AANEM Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicine Agency Accepts Marketing Authorization Applications for Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FINTEPLA (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces Positive Preliminary Results For Major Brivaracetam (Briviact[\u00ae]) Study In Asia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Reinforces Commitment to Rheumatology with 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces U.S. FDA Acceptance Of New Drug Application And EMA MAA Validation For Zilucoplan For The Treatment Of Generalized Myasthenia Gravis In Adult Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Submits Response to FDA Complete Response Letter for Bimekizumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1\/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Praxis Precision Medicines","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FINTEPLA (fenfluramine) Oral Solution Recommended for Approval in The EU For Adjunctive Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces Rozanolixizumab BLA For The Treatment Of Generalized Myasthenia Gravis Filed With U.S. FDA And Designated For Priority Review","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Pheno Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Zogenix","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"$1,900.0 million","newsHeadline":"UCB to Acquire Zogenix","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FINTEPLA (fenfluramine) Oral Solution Approved in The EU for Adjunctive Treatment of Seizures Associated with Lennox-Gastaut syndrome (LGS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cancer Research UK Signs Multi-Project Collaboration With UCB To Advance Oncology Antibody Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Aitia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB\u2019s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in prestigious The Lancet Neurology Journal","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Receives Positive CHMP Opinions for Bimekizumab for the Treatment of Adults with Psoriatic Arthritis and Axial Spondyloarthritis in the European Union","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Ariceum Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB and Ariceum Therapeutics Sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"ClearPoint Neuro","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"}]

Find Clinical Drug Pipeline Developments & Deals by UCB Pharma S.A

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the terms of the license agreement, UCB will utilize ClearPoint Neuro’s proprietary technology and services in connection with the development and commercialization of UCB’s gene therapy products.

            Lead Product(s): Gene-based Therapy

            Therapeutic Area: Technology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Recipient: ClearPoint Neuro

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration, UCB’s proprietary mRNA-display platform, ExtremeDiversity™ and Ariceum’s expertise in radiopharmaceuticals & labelling technology will enable discovery of peptide-radioisotope conjugates as potential therapeutics for immune-related diseases and cancer.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undislcosed

            Highest Development Status: Discovery Product Type: Peptide

            Recipient: Ariceum Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Bimzelx (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both IL-17A and IL-17F, two key cytokines driving inflammatory processes, received positive CHMP opinion for psoriatic arthritis and axial spondyloarthritis.

            Lead Product(s): Bimekizumab

            Therapeutic Area: Immunology Product Name: Bimzelx

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            UCB7665 (rozanolixizumab) humanized mAb that specifically binds, with high affinity, to human neonatal FcRn. Designed to block the interaction of FcRn and IgG, accelerating the catabolism of antibodies and reducing the concentration of pathogenic IgG autoantibodies.

            Lead Product(s): Rozanolixizumab

            Therapeutic Area: Immunology Product Name: UCB7665

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 13, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Bimzelx (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes, it is being investigated for moderate to severe plaque psoriasis in adults.

            Lead Product(s): Bimekizumab

            Therapeutic Area: Dermatology Product Name: Bimzelx

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration will combine the use of novel Huntington's disease drug targets from Aitia's Gemini Digital Twins with UCB's expertise in drug research and preclinical model systems in neurodegeneration to accelerate the discovery of new therapies for Huntington's disease.

            Lead Product(s): Undisclosed

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Recipient: Aitia

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration focuses on the development of two antibody candidates, UCB6114 and UCB4594 by bringing together the oncology-focused translational research and clinical development capabilities of Cancer Research UK, and UCB’s renowned antibody discovery expertise.

            Lead Product(s): UCB6114,Trifluridine,Tipiracil Hydrochloride

            Therapeutic Area: Oncology Product Name: UCB6114

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Recipient: Cancer Research UK

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Fintepla (fenfluramine) increase extracellular levels of serotonin through interaction with serotonin transporter proteins, and exhibit agonist activity at serotonin 5HT-2 receptors. It is being investigated for seizures associated with Dravet syndrome.

            Lead Product(s): Fenfluramine Hydrochloride

            Therapeutic Area: Neurology Product Name: Fintepla

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 08, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Bimzelx (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

            Lead Product(s): Bimekizumab

            Therapeutic Area: Rheumatology Product Name: Bimzelx

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement grants Pheno Therapeutics access and rights to develop, manufacture and commercialize a preclinical-stage program of novel small molecules designed to promote remyelination.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Pheno Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY